Tuberculin PPD

A sterile preparation obtained by precipitation from the heat treated products of growth and lysis of one or more strains of Mycobacterium tuberculosis and/or M.bovis. Tuberculins are used to test for hypersensitivity to tuberculo-proteins. Administration of tuberculin for sensitivity testing is by intradermal injection or by multiple-puncture devices. A person showing sensitivity to tuberculin is considered to have been infected with the tubercle bacillus

Tuberculin PPD is primarily indicated in conditions like Tuberculosis diagnosis.

Tuberculin PPD

The symptomatic adverse reactions produced by Tuberculin PPD are more or less tolerable and if they become severe, they can be treated symptomatically, these include Necrosis, Pruritus, Pain, Ulceration, Vesiculation.

A hypersensitivity or allergic reaction may occur following use of tuberculin PPD even in persons with no prior history of hypersensitivity to the product components. The tuberculin skin test should not be administered to persons who previously experienced a severe reaction (e.g., vesiculation, ulceration, necrosis) at the test site. Epinephrine must be immediately available in case an anaphylactoid or acute hypersensitivity reaction occurs. Syncope (fainting) can occur in association with administration of injectable medicines, including tuberculin PPD. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope. The predictive value of the tuberculin skin test depends on the prevalence of infection with M. tuberculosis and the relative prevalence of cross-reactions with nontuberculous mycobacteria. False positive or false negative tuberculin skin test reactions may occur in some individuals. False positive tuberculin reaction tests occur in individuals who have been infected with other mycobacteria, including vaccination with BCG. Not all infected persons will have a delayed hypersensitivity reaction to a tuberculin test. Many factors have been reported to cause a decreased ability to respond to the tuberculin test such as the presence of infections, viral infections (measles, mumps, chickenpox, HIV), live virus vaccinations (measles, mumps, rubella and other live vaccines), bacterial infections (typhoid fever, brucellosis, typhus, leprosy, pertussis, overwhelming tuberculosis, tuberculous pleurisy), fungal infections (South American blastomycosis), drugs (corticosteroids and other immunosuppressive agents), metabolic derangements (chronic renal failure), low protein states (severe protein depletion, afibrinogenemia), age (newborns, elderly patients with waned sensitivity), stress (surgery, burns, mental illness, graft-versus-host reactions), diseases affecting lymphoid organs (Hodgkin's disease, lymphoma, chronic leukemia, sarcoidosis), and malignancy. Any condition that impairs or attenuates cell mediated immunity potentially can cause a false negative reaction, including aging. Tuberculin skin test results are less reliable in HIV-infected individuals as CD4 counts decline. Avoid injecting tuberculin subcutaneously; if this occurs, no local reaction develops, but a general febrile reaction and/or acute inflammation around old tuberculous lesions may occur in highly sensitive individuals. A separate, sterile, single-use disposable syringe and needle should be used for each individual patient to prevent possible transmission of serum hepatitis virus and other infectious agents from one person to another. Special care should be taken to ensure that the product is injected intradermally and not into a blood vessel. Before administration of tuberculin PPD, review the patient's history with respect to possible immediate-type hypersensitivity to the product, determination of previous use of tuberculin PPD, and the presence of any contraindications. Epinephrine should be immediately available in case an anaphylactoid or acute hypersensitivity reaction occurs. Failure to store and handle tuberculin PPD as recommended may result in a loss of potency and inaccurate test results. Animal reproduction studies have not been conducted with tuberculin PPD. It is also not known whether the drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Tuberculin PPD should be given to a pregnant woman only if clearly needed. It is not known whether tuberculin PPD is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tuberculin PPD is administered to a nursing woman. There is no contraindication to tuberculin skin testing of infants and children. Young children (e.g., infants <6 months ofage) who are infected with M. tuberculosis may not react to tuberculin PPD. The American Academy of Pediatricians (AAP) recommends that only children who have a risk factor for TB infection or are at risk for progressing to disease, are suspected of having TB disease, or who have immunosuppressive disease or about to start immunsuppressive therapy should be tested with either a tuberculin skin test (TST) or a TB blood test. Once acquired, tuberculin sensitivity tends to persist, although it often wanes with time and advancing age. In geriatric patients, the reaction may develop more slowly and may not be maximal until after 72 hours. A number of factors have been reported to cause a decreased ability to respond to the tuberculin test, such as elderly patients with waned sensitivity. Any condition that impairs or attenuates cell mediated immunity potentially can cause a false negative reaction, including aging.

A hypersensitivity or allergic reaction may occur following use of tuberculin PPD even in persons with no prior history of hypersensitivity to the product components. The tuberculin skin test should not be administered to persons who previously experienced a severe reaction (e.g., vesiculation, ulceration, necrosis) at the test site. Epinephrine must be immediately available in case an anaphylactoid or acute hypersensitivity reaction occurs. Syncope (fainting) can occur in association with administration of injectable medicines, including tuberculin PPD. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope. The predictive value of the tuberculin skin test depends on the prevalence of infection with M. tuberculosis and the relative prevalence of cross-reactions with nontuberculous mycobacteria. False positive or false negative tuberculin skin test reactions may occur in some individuals. False positive tuberculin reaction tests occur in individuals who have been infected with other mycobacteria, including vaccination with BCG. Not all infected persons will have a delayed hypersensitivity reaction to a tuberculin test. Many factors have been reported to cause a decreased ability to respond to the tuberculin test such as the presence of infections, viral infections (measles, mumps, chickenpox, HIV), live virus vaccinations (measles, mumps, rubella and other live vaccines), bacterial infections (typhoid fever, brucellosis, typhus, leprosy, pertussis, overwhelming tuberculosis, tuberculous pleurisy), fungal infections (South American blastomycosis), drugs (corticosteroids and other immunosuppressive agents), metabolic derangements (chronic renal failure), low protein states (severe protein depletion, afibrinogenemia), age (newborns, elderly patients with waned sensitivity), stress (surgery, burns, mental illness, graft-versus-host reactions), diseases affecting lymphoid organs (Hodgkin's disease, lymphoma, chronic leukemia, sarcoidosis), and malignancy. Any condition that impairs or attenuates cell mediated immunity potentially can cause a false negative reaction, including aging. Tuberculin skin test results are less reliable in HIV-infected individuals as CD4 counts decline. Avoid injecting tuberculin subcutaneously; if this occurs, no local reaction develops, but a general febrile reaction and/or acute inflammation around old tuberculous lesions may occur in highly sensitive individuals. A separate, sterile, single-use disposable syringe and needle should be used for each individual patient to prevent possible transmission of serum hepatitis virus and other infectious agents from one person to another. Special care should be taken to ensure that the product is injected intradermally and not into a blood vessel. Before administration of tuberculin PPD, review the patient's history with respect to possible immediate-type hypersensitivity to the product, determination of previous use of tuberculin PPD, and the presence of any contraindications. Epinephrine should be immediately available in case an anaphylactoid or acute hypersensitivity reaction occurs. Failure to store and handle tuberculin PPD as recommended may result in a loss of potency and inaccurate test results. Animal reproduction studies have not been conducted with tuberculin PPD. It is also not known whether the drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Tuberculin PPD should be given to a pregnant woman only if clearly needed. It is not known whether tuberculin PPD is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when tuberculin PPD is administered to a nursing woman. There is no contraindication to tuberculin skin testing of infants and children. Young children (e.g., infants <6 months ofage) who are infected with M. tuberculosis may not react to tuberculin PPD. The American Academy of Pediatricians (AAP) recommends that only children who have a risk factor for TB infection or are at risk for progressing to disease, are suspected of having TB disease, or who have immunosuppressive disease or about to start immunsuppressive therapy should be tested with either a tuberculin skin test (TST) or a TB blood test. Once acquired, tuberculin sensitivity tends to persist, although it often wanes with time and advancing age. In geriatric patients, the reaction may develop more slowly and may not be maximal until after 72 hours. A number of factors have been reported to cause a decreased ability to respond to the tuberculin test, such as elderly patients with waned sensitivity. Any condition that impairs or attenuates cell mediated immunity potentially can cause a false negative reaction, including aging.

No adult dosage information is recorded for this medicine yet.

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Tuberculin PPD was found.

No storage information is recorded for this medicine yet.